TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

The Motley Fool Logo The Motley Fool • •By Eric Volkman
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday

Crinetics Pharmaceuticals reported Q3 earnings with lower-than-expected revenue and increased net losses, despite receiving FDA approval for its acromegaly treatment Palsonify and securing a licensing agreement with Sanwa Kagaku Kenkyusho.

Insights
CRNX   negative

Stock dropped 8.03% due to missing analyst revenue expectations and increased net losses, despite positive developments like FDA drug approval and new licensing agreement